Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

neuraxpharm bohemia s.r.o., Česká republika - pramipexol - 27 - antiparkinsonica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

neuraxpharm bohemia s.r.o., Česká republika - pramipexol - 27 - antiparkinsonica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

neuraxpharm bohemia s.r.o., Česká republika - pramipexol - 27 - antiparkinsonica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

neuraxpharm bohemia s.r.o., Česká republika - pramipexol - 27 - antiparkinsonica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

neuraxpharm bohemia s.r.o., Česká republika - pramipexol - 27 - antiparkinsonica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

novartis slovakia s.r.o., slovensko - karbamazepín - 21 - antiepileptica, anticonvulsiva

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ardez pharma, spol. s r.o., Česká republika - vazopresín (argipresín) - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Európska únia - slovenčina - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Európska únia - slovenčina - EMA (European Medicines Agency)

ecuphar nv - enflicoxib - proti zápalové a protireumatické produkty - psy - for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.

Európska únia - slovenčina - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastické činidlá - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pacienti, ktorí majú nízky alebo veľmi nízke riziko opakovania by nemalo prijímať adjuvantná liečba. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. okrem novo diagnostikovaných chronickej fáze cml, nie sú tam žiadne kontrolovaných štúdií dokazuje, klinický prospech alebo zvýšené prežitie týchto ochorení.